FORM 5

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasimigton,	D.O.	200-0

 ~=	~ 11	 	 	-101		

OMB APP	PROVAL
OMB Number:	3235-0362
Estimated average	burden

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Form 3	Holdings Repo		OWNERSHIP									hours per response:			1.0			
Form 4	Transactions R	eported.	File	ed pursuant to or Sectior					ities Excha ompany Ac									
1. Name and Address of Reporting Person* <u>Kumar Neil</u>					2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]							5. Relationship of F (Check all applicab X Director			,		Issuer Owner	
	(Fir DGEBIO PI LING STRE	HARMA, INC.	Middle)		3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2019						Year)	X Officer (give title below) See Re				Other (specify below)		
(Street) PALO ALTO CA 94301				4. If Amen	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	,				son	
(City)	(Sta	ate) (Zip)										1 010					
		Tabl	e I - Non-Deriv	ative Sec	uritie	es Ac	quire	ed, Dis	sposed (of, or	Benefic	ially	Owne	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)		Execution Date, if any		3. Transaction Code (Instr.		4. Securities Acquired (A) or Dispos (D) (Instr. 3, 4 and 5)				Securitie Benefici		es ally		ership I n: Direct E	7. Nature of Indirect Beneficial			
				(Month/Day/1	reary	8)		Amoun	ount (A) or (D) Price		Price		Issuer's	ssuer's Fiscal ear (Instr. 3 and			Ownership (Instr. 4)	
Common Stock			12/30/2019			G		400,375 D		D	\$0.00)	0		I		By Neil Kumar LLC ⁽¹⁾	
Common Stock 12/30/2019					G		+	66,730 A		\$0.00	00 4,6		4,685,365		D			
		Та	ble II - Derivat (e.g., p	ive Secur uts, calls,	ities warı	Acqu rants,	ıired opti	, Disp ions, c	osed of, converti	or Be	neficial curities	ly O	wned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security				Transaction Code (Instr.	ansaction of Expir ode (Instr. Derivative (Mont		nte Exerc ration Da tth/Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Der Sec (Ins	Price of ivative curity str. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		

Explanation of Responses:

1. The shares were originally held by Neil Kumar LLC, of which the Reporting Person shared voting, investment and dispositive power with the other LLC member. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares were beneficially owned by the Reporting Person for Section 16 or any other purposes.

Date Exercisable **Expiration**

Remarks:

Title: Chief Executive Officer and President

/s/ Brian Stephenson, Attorneyin-Fact 02/12/2020

of Shares

Title

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Brian C. Stephenson, Tara Condon, Yi Ching Yau and Jonathan Barr, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-infact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of BridgeBio Pharma, Inc. (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedule 13D and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or any amendment(s) thereto, and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in- fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of, or legal counsel to the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of February 12, 2020.

/s/ Neil Kumar